Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Has Average Target Price of $22.57
Vir Biotechnology (NASDAQ:VIR) Stock Price Breaks Below 200-Day Moving Average - Here's Why
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's Why - Stock Observer
Vir Bio secures US$150m ahead of London healthcare conference
Vir Biotechnology Shares Fall 18% On Pricing Of $150 Mln Shares Offering
Vir Biotechnology stock tumbles on $150M share offering
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $28.00 - Zolmax
Vir Biotechnology, Inc. $VIR Stock Sold by Pictet Asset Management Holding SA - Markets Daily
Does Phase 3 Trial Success Change The Bull Case For Vir Biotechnology (VIR)?
Vir Biotechnology, Inc. $VIR Stock: Pictet Asset Management Holding SA Cuts Holdings - Stock Observer
What is HC Wainwright's Estimate for VIR FY2026 Earnings? - Daily Political
Vir Biotechnology (NASDAQ:VIR) Stock Gets Price Target Bump from Morgan Stanley
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain
Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints
VIR Reiterates by HC Wainwright & Co. -- Price Target Maintained
Vir hepatitis D drug succeeds in first pivotal study
HC Wainwright Reaffirms "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology Stock Jumps 14%
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Time to Buy?
Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win
Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be
Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success
VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever - Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data | Morningstar
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta | Morningstar
Vir Biotechnology (NASDAQ:VIR) Upgraded to Buy at Wall Street Zen - Daily Political
Vir Biotechnology Stock Gets Focus As Phase 3 Hepatitis Delta Data Head To AASLD
Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50 Day Moving Average - Should You Sell?
Vir Biotechnology (NASDAQ:VIR) Upgraded at Wall Street Zen
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High on Analyst Upgrade
Vir Biotechnology (NASDAQ:VIR) Sets New 12-Month High Following Analyst Upgrade - Zolmax
Vir Biotechnology (NASDAQ:VIR) Raised to "Hold" at Zacks Research - Zolmax
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Zacks Research
Needham & Company LLC Issues Positive Forecast for Vir Biotechnology (NASDAQ:VIR) Stock Price
Vir Biotechnology Inc (VIR) (Q3 2026) Earnings Call Highlights: Hepatitis Delta Data on Deck ...
Narrower Losses Could Be A Game Changer For Vir Biotechnology (VIR)
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call - Daily Political
Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in Stock
Vir Biotechnology (NASDAQ:VIR) EVP Sells $26,717.70 in Stock - Stock Observer
Vir Biotechnology (NASDAQ:VIR) Stock: Insider Verneuil Vanina De Sells 1,343 Shares - Daily Political
Head-To-Head Review: Vir Biotechnology (NASDAQ:VIR) & BioCryst Pharmaceuticals (NASDAQ:BCRX) - Daily Political
Vir Biotechnology (NASDAQ:VIR) Reaches New 52-Week High - Should You Buy?
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - What's Next?
Gilead Cancer Deal Could Be A Game Changer For Vir Biotechnology (VIR)
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's What Happened - Stock Observer
Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday
Vir Biotechnology (NASDAQ:VIR) Shares Cross Above 50-Day Moving Average - What's Next?
Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal?
Comparing Vir Biotechnology (NASDAQ:VIR) and REGENXBIO (NASDAQ:RGNX) - Markets Daily
Vir Biotechnology, Inc. (VIR) - What Are Investment Firms Thinking About This Stock?
VirBiotechnology News
Will Jensen Huang Return as Nvidia CEO? What It Means for NVDA Stock
Nvidia Stock Forecast After Jensen Huang Resigns: Buy the Dip or Wait?
Micron Stock Price Forecast 2026–2030: Can AI Memory Demand Reverse a 26% Week-to-Date Sell-Off?
Latest news
Show more
AMD Stock Rises 5.3% as Nvidia’s $130 Billion Outlook Signals Strong AI Demand
Bank of America Stock Falls to $48.91 After Berkshire Cuts Stake Again
Bitcoin Slides Toward $62,000 as ETF Outflows Mount and Fed Rate Hike Bets Persist
Anthropic IPO Prices at $83 and Raises $81.3 Billion: How High Can ANT Stock Open?
Gold Price Today : Spot Gold Rebounds to $3,755 as Fed Rate Hike Risk Persists
Alibaba Earnings Today: Can AI Cloud Growth Offset China’s Consumer Slowdown?
